Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jan 14;210(1):99–114. doi: 10.1084/jem.20121172

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 Peppa et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 6. — TRAIL-R2 expression is a feature of CD8⁺ T cells encountering antigen in the HBV-infected liver. (A) Representative gating strategy identifying intrahepatic TRAIL-R2⁺ high (red), TRAIL-R2⁺ low (black), and TRAIL-R2 negative (gray) CD8⁺ T cells from a CHB patient. Histograms and bars depict the proportions of CD38 (n = 4), Annexin V (n = 3), PD1 (n = 6), and CD57 (n = 8) expressed by each subset directly ex vivo. (B) The maturation status of intrahepatic TRAIL-R2⁺ high (red), TRAIL-R2⁺ low (black), and TRAIL-R2 negative (gray) CD8⁺ T cells were analyzed by co-staining for CD27 and CD45RA. Representative FACS plot and summary bars of frequencies of expression of TRAIL-R2⁺ high (red), TRAIL-R2⁺ low (black), and TRAIL-R2 negative (gray) CD8⁺ T cells with naive, central memory (CM), effector memory (EM) and revertant (EMRA) phenotypes from n = 4 CHB patients. (C) Summary bar graphs comparing expression of TRAIL-R2 on global intrahepatic CD8⁺ T cells, CMV-specific and HBV-specific CD8⁺ T cells. Virus-specific CD8⁺ T cells were identified directly ex vivo by multimer staining in (n = 5) HLA-A2⁺ CHB patients with available liver biopsies. (D) Representative examples of the gating strategy from a control patient with no evidence of viral hepatitis (control liver) and a CHB patient (HBV liver) showing expression of TRAIL-R2 on intrahepatic global CD8⁺ T cells and virus-specific CD8⁺ T cells identified via IFN-γ staining after overnight stimulation with CMV peptide and HBV overlapping peptides (OLP), respectively. Summary bar graphs comparing expression of TRAIL-R2 on CMV-specific CD8⁺ T cells from control livers (n = 5) versus CMV and HBV-specific CD8⁺ T cells from (n = 5) CHB patients. Bars represent the mean ± SEM. *, P < 0.05.